Potential role of metalloproteinase inhibitors from radiation‑sterilized             amnion dressings in the healing of venous leg ulcers.
Chronic wounds are a significant socio-economic problem, thus, the improvement of the effectiveness of their treatment is an important objective for public health strategies. The predominant stage of the chronic wound is the inflammatory reaction which is associated with the damage of tissues, possibly due to the excessive secretion and activation of matrix metalloproteinases (MMPs). Several reports have suggested that amnion dressing inhibits tissue destruction and accelerates wound healing. Our recent study revealed that sterilized amnion stimulates keratinocyte proliferation in vitro, while the present study focused on the clinical application of radiation-sterilized amnion in chronic venous leg ulcers and aimed to explain the possible mechanism of its in vivo action. The study involved 25 individuals suffering from venous leg ulceration with a surface area of 10-100 cm2 and a healing rate below 10% per week, as verified during a 2-week screening period. The effectiveness of the amnion dressing was estimated following 4 weeks of treatment. The wound assessment, based on a modified Bates-Jensen Questionnaire, revealed a good and satisfactory response to the treatment in 23 of the 25 patients. The measurement of MMP-2 and MMP-9 activities in wound exudates revealed a decrease in activity in response to amnion application. This effect resulted from the presence of the potent MMP inhibitors, tissue inhibitor of metalloproteinases-1 (TIMP-1), type-1 plasminogen activator inhibitor (PAI-1) and thrombospondin-1 (TSP-1) in the amnion dressings, as shown by real-time fluorescence zymography and protein microarrays. Thus, unlike modern synthetic dressing materials, radiation-sterilized amnion dressings may have a multidirectional beneficial effect on chronic wounds.
Department of Histology and Embryology, Warsaw Medical University,                     Warsaw, Poland.
Małgorzata
M
Litwiniuk
Barbara
B
Bikowska
Justyna
J
Niderla-Bielińska
Jarosław
J
Jóźwiak
Artur
A
Kamiński
Piotr
P
Skopiński
Tomasz
T
Grzela
D000368:Aged; D000369:Aged, 80 and over; D000650:Amnion / Q000378:metabolism*; D001458:Bandages; D005260:Female; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000737:chemistry / Q000378:metabolism; D020780:Matrix Metalloproteinase 9 / Q000737:chemistry / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors / Q000627:therapeutic use*; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000627:therapeutic use; D040081:Protein Array Analysis; D013242:Sterilization; D019700:Thrombospondin 1 / Q000627:therapeutic use; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000627:therapeutic use; D014647:Varicose Ulcer / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D014945:Wound Healing
D061965:Matrix Metalloproteinase Inhibitors; D017395:Plasminogen Activator Inhibitor 1; D019700:Thrombospondin 1; D019715:Tissue Inhibitor of Metalloproteinase-1; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9